Actively Recruiting
Study of Disseminated Borreliosis in Patients Treated with Anti-CD20 Antibodies in France
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
4 weeks
Total Duration
AI-Summary
What this Trial Is About
This research investigates cases of disseminated borreliosis, an infection caused by Borrelia burgdorferi sl. and Borrelia miyamotoi, in patients who have received treatment with anti-CD20 monoclonal antibodies. The study aims to clinically, biologically, radiologically, and pharmacologically describe these cases to better understand the infection among this specific patient group in France. The study is observational and collects data from patients who developed disseminated borreliosis within 24 months after receiving anti-CD20 therapy between January 2010 and July 2025. It does not involve administering treatments but focuses on monitoring and describing the diseases presentation and course. Participants will be evaluated for up to 12 months, during which researchers will document the clinical presentation of borreliosis cases. The study involves collecting medical information and biological data to characterize the infection. There is no intervention, and participants usual medical care continues throughout the observation period.
CONDITIONS
Brief Title
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Research Team
P
Pierre BOYER, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
